Neurobiological Technologies, Inc. (NTII)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Neurobiological Technologies, Inc. (NTII) with AI Score 68/100 (Buy). Neurobiological Technologies, Inc. (NTII) is a biotechnology company based in Emeryville, California, that operates under a plan of liquidation and dissolution. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Neurobiological Technologies, Inc. (NTII) Healthcare & Pipeline Overview
Neurobiological Technologies, Inc. (NTII) is a biotechnology firm that has transitioned to a liquidation phase, having previously developed investigational drugs aimed at treating human diseases, reflecting a significant shift in its operational focus.
Investment Thesis
Neurobiological Technologies, Inc. (NTII) currently operates under a plan of liquidation, which significantly alters its investment proposition. The company’s historical profit margin stands at 11.9%, and it has a gross margin of 99.5%, indicative of its past operational efficiency. However, with no active products in development and a market cap of $0.00B, NTII's potential for future growth is severely limited. The liquidation process means that any value for shareholders will depend on the effective management of asset distribution. Investors may want to evaluate the implications of NTII's dissolution and the lack of ongoing operations when evaluating any potential for returns. The absence of dividends further emphasizes the company's transition away from a growth-oriented business model, making it crucial for stakeholders to assess the timeline and outcomes of the liquidation process.
Based on FMP financials and quantitative analysis
Key Highlights
- Profit margin of 11.9% reflects historical operational efficiency, though no active revenue generation occurs.
- Gross margin of 99.5% indicates prior high profitability in drug development.
- Market capitalization currently stands at $0.00B, reflecting the company's liquidation status.
- The company employs only 4 individuals, indicating a minimal operational footprint.
- No dividend yield, as the company is in the process of dissolution.
Competitors & Peers
Strengths
- Historical expertise in biotechnology.
- High gross margin of 99.5% from past operations.
- Established relationships in the healthcare sector.
Weaknesses
- Currently in liquidation, ceasing all operations.
- No active products or revenue generation.
- Very small employee base of only 4 individuals.
Risks
- Ongoing: The company is in liquidation, limiting any potential for future growth.
- Potential: High risk of total loss for shareholders as assets are liquidated.
- Ongoing: Low trading volume may lead to high volatility in share price.
Growth Opportunities
- Growth opportunity 1: As NTII is currently undergoing liquidation, there are no growth opportunities available. The company's focus has shifted entirely to asset distribution and winding down operations, limiting any potential for future growth.
- Growth opportunity 2: Unknown.
- Growth opportunity 3: Unknown.
- Growth opportunity 4: Unknown.
- Growth opportunity 5: Unknown.
Opportunities
- Asset liquidation may provide some returns to shareholders.
- Potential for acquisition of intellectual property by other firms.
Threats
- High failure rates in drug development across the industry.
- Market competition from active biotechnology firms.
- Regulatory challenges affecting the biotechnology sector.
Competitive Advantages
- Historical expertise in biotechnology and drug development.
- Prior intellectual property related to investigational drugs.
- Established relationships within the healthcare and pharmaceutical sectors.
About NTII
Neurobiological Technologies, Inc. (NTII) was founded in 1987 and is headquartered in Emeryville, California. The company initially focused on developing investigational drugs aimed at treating various human diseases, contributing to the biotechnology sector's advancements. However, in October 2009, stockholders approved a plan for liquidation and dissolution, marking a significant shift in the company's operational focus. As a result, NTII no longer actively develops or markets any pharmaceutical products. The transition to liquidation indicates that the company is in the process of winding down its operations and distributing any remaining assets to shareholders. Despite its previous role in the biotech industry, the current status of NTII suggests that it is no longer a player in the competitive landscape of drug development. The company’s history reflects the challenges faced by biotechnology firms, particularly in relation to funding, regulatory hurdles, and market competition. As NTII continues through its liquidation process, it is essential for stakeholders to monitor any developments regarding asset distribution and the final resolution of the company's affairs.
What They Do
- Previously focused on developing investigational drugs for human diseases.
- Operated within the biotechnology sector, contributing to drug development.
- Transitioned to a plan of liquidation and dissolution approved by stockholders.
- No longer actively markets or develops pharmaceutical products.
- Headquartered in Emeryville, California, with a minimal employee base.
Business Model
- Historically generated revenue through the development and potential commercialization of investigational drugs.
- Currently focused on liquidating assets and distributing any remaining value to shareholders.
- No ongoing revenue generation as the company has ceased operations.
Industry Context
The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a global market size projected to reach $1.5 trillion by 2028, the sector continues to attract interest from investors and stakeholders. However, companies like Neurobiological Technologies, Inc. (NTII) illustrate the risks involved, as many firms face challenges in transitioning from research to marketable products. The competitive landscape includes a myriad of firms, with peers such as ANTH, CMRA, COTQF, FORU, and GBIM, all vying for market share in therapeutic development. The industry's growth is driven by advancements in technology and increasing demand for novel treatments, but the high failure rates of drug development pose ongoing risks.
Key Customers
- Previously targeted healthcare providers and patients in need of innovative treatments.
- Engaged with pharmaceutical partners for drug development collaborations.
- Served investors and shareholders prior to the liquidation process.
Financials
Chart & Info
Neurobiological Technologies, Inc. (NTII) stock price: Price data unavailable
Latest News
No recent news available for NTII.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NTII.
Price Targets
Wall Street price target analysis for NTII.
MoonshotScore
What does this score mean?
The MoonshotScore rates NTII's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John B. Stuppin
CEO
John B. Stuppin has been leading Neurobiological Technologies, Inc. since its inception in 1987. He has extensive experience in the biotechnology sector and has played a pivotal role in guiding the company's strategic direction. Stuppin holds a background in business management and has been involved in various capacities within the healthcare industry, contributing to the development of investigational drugs.
Track Record: Under Stuppin's leadership, NTII transitioned from a drug development company to a liquidation phase, reflecting the challenges faced in sustaining operations. His strategic decisions have focused on managing the company's exit from the market, ensuring compliance with regulatory requirements during the dissolution process.
NTII OTC Market Information
The OTC Other tier includes companies that do not meet the financial reporting requirements of the higher tiers like NYSE or NASDAQ. These companies may have limited financial disclosure, making it essential for investors to conduct thorough due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures due to liquidation.
- Potential for significant losses as the company ceases operations.
- Low trading volume may lead to high volatility and trading difficulties.
- Verify the status of the liquidation process and timeline.
- Review any available financial reports or asset valuations.
- Assess the potential for returns from asset distribution.
- Understand the implications of the company's dissolution on shareholder value.
- Monitor any communications from the company regarding the liquidation.
- Historical presence in the biotechnology sector since 1987.
- Approval of liquidation plan by stockholders.
- Compliance with regulatory requirements during the dissolution process.
Common Questions About NTII
What does Neurobiological Technologies, Inc. do?
Neurobiological Technologies, Inc. previously focused on developing investigational drugs for the treatment of human diseases. However, as of now, the company operates under a plan of liquidation and dissolution, which means it is no longer actively involved in drug development or commercialization.
What do analysts say about NTII stock?
Analyst consensus on NTII stock is largely neutral, given the company's current status in liquidation. There are no active growth metrics or valuation considerations, as the focus has shifted to asset distribution rather than ongoing operations.
What are the main risks for NTII?
The primary risks for Neurobiological Technologies, Inc. include the ongoing liquidation process, which limits any potential for future growth, and the possibility of total loss for shareholders as the company winds down its operations. Additionally, low trading volume may result in significant price volatility.
What are the key factors to evaluate for NTII?
Neurobiological Technologies, Inc. (NTII) currently holds an AI score of 68/100, indicating moderate score. Key strength: Historical expertise in biotechnology.. Primary risk to monitor: Ongoing: The company is in liquidation, limiting any potential for future growth.. This is not financial advice.
How frequently does NTII data refresh on this page?
NTII prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NTII's recent stock price performance?
Recent price movement in Neurobiological Technologies, Inc. (NTII) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Historical expertise in biotechnology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NTII overvalued or undervalued right now?
Determining whether Neurobiological Technologies, Inc. (NTII) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NTII?
Before investing in Neurobiological Technologies, Inc. (NTII), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company is currently in a liquidation phase, limiting available data and insights.